Nkcfo LLC Has $83,000 Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Nkcfo LLC cut its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 33.3% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 170 shares of the company’s stock after selling 85 shares during the quarter. Nkcfo LLC’s holdings in IDEXX Laboratories were worth $83,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Atomi Financial Group Inc. lifted its position in IDEXX Laboratories by 3.4% during the 1st quarter. Atomi Financial Group Inc. now owns 637 shares of the company’s stock worth $344,000 after buying an additional 21 shares in the last quarter. Ballentine Partners LLC lifted its position in shares of IDEXX Laboratories by 1.9% during the first quarter. Ballentine Partners LLC now owns 1,188 shares of the company’s stock worth $641,000 after purchasing an additional 22 shares in the last quarter. Eads & Heald Wealth Management lifted its position in shares of IDEXX Laboratories by 0.8% during the second quarter. Eads & Heald Wealth Management now owns 2,686 shares of the company’s stock worth $1,309,000 after purchasing an additional 22 shares in the last quarter. LRI Investments LLC grew its stake in shares of IDEXX Laboratories by 21.7% during the second quarter. LRI Investments LLC now owns 129 shares of the company’s stock valued at $63,000 after purchasing an additional 23 shares during the last quarter. Finally, Mather Group LLC. increased its holdings in shares of IDEXX Laboratories by 4.2% in the second quarter. Mather Group LLC. now owns 594 shares of the company’s stock valued at $321,000 after purchasing an additional 24 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have issued reports on IDXX. Stifel Nicolaus reduced their price objective on IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating on the stock in a report on Monday, June 24th. BTIG Research assumed coverage on IDEXX Laboratories in a research report on Thursday, July 25th. They issued a “buy” rating and a $580.00 price objective for the company. StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, July 10th. Finally, Piper Sandler cut their price target on shares of IDEXX Laboratories from $600.00 to $520.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 14th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, IDEXX Laboratories has an average rating of “Moderate Buy” and an average price target of $582.25.

IDEXX Laboratories Price Performance

Shares of IDXX opened at $506.74 on Friday. The stock has a 50 day simple moving average of $483.85 and a 200 day simple moving average of $499.57. IDEXX Laboratories, Inc. has a 52-week low of $372.50 and a 52-week high of $583.39. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.03 and a current ratio of 1.37. The firm has a market capitalization of $41.85 billion, a PE ratio of 49.06, a P/E/G ratio of 4.17 and a beta of 1.33.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Tuesday, August 6th. The company reported $2.44 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.88 by ($0.44). The firm had revenue of $1 billion for the quarter, compared to the consensus estimate of $1.01 billion. IDEXX Laboratories had a return on equity of 57.03% and a net margin of 22.34%. IDEXX Laboratories’s revenue for the quarter was up 6.4% on a year-over-year basis. During the same quarter last year, the company posted $2.67 EPS. Sell-side analysts predict that IDEXX Laboratories, Inc. will post 10.45 EPS for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.